| abstract |
The present disclosure relates to a chemical moiety that, when bound to a pharmacophore, undergoes first-pass metabolism. By undergoing primary metabolism, the bioavailability of the pharmacophore can be lowered. Such compounds and related pharmaceutical compositions can be used for targeted treatment of diabetic and non-diabetic gastrointestinal disorders while minimizing systemic circulation across the gastrointestinal tract. |